Loss of CD7, independent of galectin‐3 expression, implies a worse prognosis in adult T‐cell leukaemia/lymphoma

Liu, Ting-Yun; Chen, Chien-Yuan; Tien, Hwei‐Fang; Lin, Chung-Wu

doi:10.1111/j.1365-2559.2008.03199.x

Cited by 20 publications

(11 citation statements)

References 30 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, downregulation of CD7 is also related to the progression of adult T-cell lymphoma/leukemia where galectin-3-induced apoptosis is inhibited, 83 although Twist2 expression has not yet been detected in this context.…”

Section: Twist1–2 As Emerging Risk Factors In Hematological Malignanciesmentioning

confidence: 99%

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies

Mérindol

Riquet

Szablewski

et al. 2014

Blood Cancer Journal

View full text Add to dashboard Cite

Twist1 and Twist2 (Twist1–2) are two transcription factors, members of the basic helix-loop-helix family, that have been well established as master transcriptional regulators of embryogenesis and developmental programs of mesenchymal cell lineages. Their role in oncogenesis in epithelium-derived cancer and in epithelial-to-mesenchymal transition has also been thoroughly characterized. Recently, emerging evidence also suggests a key role for Twist1–2 in the function and development of hematopoietic cells, as well as in survival and development of numerous hematological malignancies. In this review, we summarize the latest data that depict the role of Twist1–2 in monocytes, T cells and B lymphocyte activation, and in associated hematological malignancies.

show abstract

Section: Twist1–2 As Emerging Risk Factors In Hematological Malignanciesmentioning

confidence: 99%

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies

Mérindol

Riquet

Szablewski

et al. 2014

Blood Cancer Journal

View full text Add to dashboard Cite

show abstract

“…The currently used immunophenotypic criterion for ATL diagnosis is CD3 + CD4 + CD25 + CD7 − . However, this definition has significant shortcomings: CD4 + CD25 + CD7 − is also the immunophenotype of infected cells in non‐ATL HTLV‐1 infection, and ATL with a CD25 − or CD7 + immunophenotype has been commonly reported; so these markers lack sensitivity and specificity for the diagnosis of ATL .…”

Section: Discussionmentioning

confidence: 99%

“…CD7 is an immunoglobulin superfamily receptor involved in apoptosis regulation and is expressed on normal CD4 T cells. CD7 expression is frequently lost in ATL and is associated with poor prognosis . CD26/dipeptidyl peptidase IV (DPPIV), a T‐cell‐activation antigen, is expressed on normal CD4 T cells.…”

Section: Introductionmentioning

confidence: 99%

Risk stratification of adult T‐cell leukemia/lymphoma using immunophenotyping

et al. 2016

View full text Add to dashboard Cite

Adult T‐cell leukemia/lymphoma (ATL), a human T‐lymphotropic virus type 1 (HTLV‐1)‐associated disease, has a highly variable clinical course and four subtypes with therapeutic and prognostic implications. However, there are overlapping features between ATL subtypes and between ATL and nonmalignant (non‐ATL) HTLV‐1 infection complicating diagnosis and prognostication. To further refine the diagnosis and prognosis of ATL, we characterized the immunophenotype of HTLV‐1‐infected cells in ATL and non‐ATL. A retrospective study of peripheral blood samples from 10 HTLV‐1‐uninfected subjects (UI), 54 HTLV‐1‐infected patients with non‐ATL, and 22 with ATL was performed using flow cytometry. All patients with ATL had CD4+ CCR4+ CD26− immunophenotype and the frequency of CD4+ CCR4+ CD26− T cells correlated highly significantly with the proviral load in non‐ATL suggesting CD4+ CCR4+ CD26− as a marker of HTLV‐1‐infected cells. Further immunophenotyping of CD4+ CCR4+ CD26− cells revealed that 95% patients with ATL had a CD7− (≤30% CD7+ cells), whereas 95% HTLV+ non‐ATL had CD7+ (>30% CD7+ cells) immunophenotype. All patients with aggressive ATL had a CCR7+ (≥30%), whereas 92% with indolent ATL and 100% non‐ATL had a CCR7− (<30%) immunophenotype. Patients with nonprogressing indolent ATL were CD127+ but those with progressive lymphocytosis requiring systemic therapy had a CD127− (≤30%) immunophenotype. In summary, HTLV‐1‐infected cells have a CD4+ CCR4+ CD26− immunophenotype. Within this population, CD7− phenotype suggests a diagnosis of ATL, CCR7+ phenotype identifies aggressive ATL, while CCR7− CD127− phenotype identifies progressive indolent ATL.

show abstract

“…In Sz patients, expression of CD7 and CD7 mediated galectin-1-induced apoptosis is reduced [109]. The reduced expression of CD7 is also associated with progression of adult T-cell lymphoma/leukemia [110].…”

Section: Lymphomasmentioning

confidence: 99%

Twist as a new prognostic marker in hematological malignancies

et al. 2015

View full text Add to dashboard Cite

Twist proteins are members of basic helix-loop-helix family and are major regulators of embryogenesis. In adult humans, Twist proteins are mainly expressed in precursor cells, including myogenic, osteoblastic, chondroblastic and myelomonocytic lineages, maintaining their undifferentiated state. In addition, they play important roles in lymphocyte function and maturation. Recently, several studies have reported regulatory roles for Twist in the function and development of hematopoietic cells as well as in survival and development of numerous hematological malignancies. It is activated by numerous signal transduction pathways, including Akt, nuclear factor κB, Wnt, signal transducer and activator of transcription 3, mitogen-activated protein kinase and Ras signaling. Activated Twist has an anti-apoptotic role and protects cancer cells from apoptotic cell death. In addition, overexpression of Twist promotes the process of epithelial-mesenchymal transition, which has an essential role in cancer metastasis. Hereby, we review the aberrant expression of Twist in hematopoietic malignancies such as leukemias, lymphomas and myelodysplastic syndrome, which is related with poor prognosis and drug resistance in these disorders. Inactivation of Twist by small RNAs technology or chemotherapeutic inhibitors targeting Twist and upstream or downstream molecules of Twist signaling pathways may be helpful in management of disease to improve treatment strategies in malignancies.

show abstract

Loss of CD7, independent of galectin‐3 expression, implies a worse prognosis in adult T‐cell leukaemia/lymphoma

Abstract: These data suggest that, by down-regulating CD7, ATLL cells could have escaped Gal-3-induced apoptosis to run a more aggressive clinical course.

Cited by 20 publications

References 30 publications

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies

The emerging role of Twist proteins in hematopoietic cells and hematological malignancies

Risk stratification of adult T‐cell leukemia/lymphoma using immunophenotyping

Twist as a new prognostic marker in hematological malignancies

Contact Info

Product

Resources

About